Stock Events

Stock Events

Insulet 

€142.75
0
-€3.9-2.66% Tuesday 19:55

Statistics

Day High
146.3
Day Low
142.6
52W High
302.3
52W Low
142.75
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6MayExpected
Q4 2025
Next
1.02
1.12
1.22
1.31
Expected EPS
1.02296883368
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GOV.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Tandem Diabetes Care
TNDM
Mkt Cap1.33B
Tandem Diabetes Care, Inc. competes directly with Insulet by offering insulin pump therapy for diabetes management, which is a direct alternative to Insulet's Omnipod system.
Medtronic
MDT
Mkt Cap102.71B
Medtronic plc is a major competitor in the insulin pump market, offering a range of products that compete with Insulet's offerings for diabetes management.
Dexcom
DXCM
Mkt Cap23.67B
DexCom, Inc. provides continuous glucose monitoring (CGM) systems that are often used in conjunction with insulin pumps like those offered by Insulet, making them a competitor in the broader diabetes management space.
Abbott Laboratories
ABT
Mkt Cap155.82B
Abbott Laboratories offers the FreeStyle Libre, a CGM system that competes with the integrated diabetes management solutions provided by Insulet.
Insulet
PODD
Mkt Cap12.12B
Insulet Corporation is listed as its own competitor due to an error. Please disregard this entry.
Senseonics
SENS
Mkt Cap213.2M
Senseonics Holdings, Inc. offers the Eversense CGM system, which competes in the diabetes management market by providing an alternative to the CGM solutions that can be used with Insulet's products.
Novo Nordisk
NVO
Mkt Cap194.57B
Novo Nordisk A/S is a leading provider of insulin and other diabetes care products that, while not a direct competitor in the insulin pump market, competes in the broader diabetes management space.
Sanofi
SNY
Mkt Cap110.4B
Sanofi provides a range of diabetes care solutions, including insulin therapies that compete with the insulin management solutions offered by Insulet.
Mannkind
MNKD
Mkt Cap876.98M
MannKind Corporation offers Afrezza, an inhaled insulin, providing a non-injectable alternative to insulin delivery that competes with traditional pump therapies like those offered by Insulet.

About

There is no Profile data available for GOV.MU.
Show more...
CEO
ISIN
US45784P1012

Listings

MI
IT
1PODD.MI
LSE
GB
0ADR.LSE
MU
DE
GOV.MU
STU
DE
GOV.STU

0 Comments

Share your thoughts

FAQ

What is Insulet stock price today?▼
The current price of GOV.STU is €142.75 EUR — it has decreased by -2.66% in the past 24 hours. Watch Insulet stock price performance more closely on the chart.
What is Insulet stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Insulet stocks are traded under the ticker GOV.STU.
Is Insulet stock price growing?▼
GOV.STU stock has fallen by -3.94% compared to the previous week, the month change is a -19.26% fall, over the last year Insulet has showed a -37.06% decrease.
In which sector is Insulet located?▼
Insulet operates in the Other sector.
When did Insulet complete a stock split?▼
Insulet has not had any recent stock splits.